Vaccine expert Novax (Nasdaq stock code: NVAX) The stock sell-off on Monday could not be stopped. Although the company reported seemingly good news, investors fled the stock, causing the stock price to fall by nearly 10% that day.
The good news is that Novavax is launching a Phase 3 clinical trial of NVX-CoV2373, which has entered the coronavirus race. The company plans to recruit 30,000 participants to participate in the PREVENT-19 study, which will be conducted in approximately 115 locations in the United States and Mexico.
Like other coronavirus vaccine developers, Novavax is supported by the US government’s “Warp Speed Operation”
In addition to early clinical trials in South Africa, the United States and Australia, the biotech company is also conducting a Phase 3 study of NVX-CoV2373 in the United Kingdom.
Earlier this month, two coronavirus vaccines have received emergency use authorization from the US Food and Drug Administration. They are all, modernMRNA-1273 and Pfizer/Biological TechnologyThe BNT162b2 has been managed nationwide.
How to do
Since NVX-CoV2373 has just entered the third phase of large-scale testing, Novavax is far behind Moderna, Pfizer and BioNTech. Even with a certain degree of subsidy, the leader of this game will still get a lot of benefits from mass vaccination; for some investors, Novavax may be considered too backward.